Vanda Pharmaceuticals (VNDA) Change in Receivables (2010 - 2026)

Vanda Pharmaceuticals has reported Change in Receivables for 17 years, with the latest figure at $2.3 million in Q1 2026.

• Quarterly Change in Receivables rose 192.07% year-over-year to $2.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.3 million (up 56.25% YoY) and the FY2025 annual result came in at $7.5 million, down 42.65% from the prior year.
• Change in Receivables declined to $2.3 million in Q1 2026 per VNDA's latest filing, from $4.1 million in the prior quarter.
• Over five years, Change in Receivables peaked at $9.1 million in Q2 2023 and troughed at -$8.9 million in Q1 2023.
• A 5-year average of $1.4 million and a median of $2.3 million in 2026 frame the typical range for Change in Receivables.
• The widest YoY moves for Change in Receivables: up 662.42% in 2023, down 829.85% in 2023.
• Over 5 years, Change in Receivables stood at $4.1 million in 2022, then rose by 18.79% to $4.8 million in 2023, then fell by 8.37% to $4.4 million in 2024, then fell by 8.03% to $4.1 million in 2025, then plunged by 42.75% to $2.3 million in 2026.
• According to Business Quant data, Change in Receivables over the past three periods registered $2.3 million, $4.1 million, and $5.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.